Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Theravance Biopharma, Inc. (TBPH : NSDQ)

• Company Description    Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.? Number of Employees: 90

• Price / Volume Information    Yesterday's Closing Price: $17.01 Daily Weekly Monthly 20 Day Moving Average: 356,873 shares Shares Outstanding: 51.92 (millions) Market Capitalization: $883.14 (millions) Beta: 0.25 52 Week High: $21.03 52 Week Low: $13.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.53% 2.40% 12 Week 2.59% 0.50% Year To Date -9.09% -17.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 901 GATEWAY BOULEVARD - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-808-6000 fax: - investor.relations@theravance.com http://www.theravance.com

• General Corporate Information    Officers Rick E Winningham - Chief Executive Officer Susannah Gray - Chairperson of the Board of Directors Aziz Sawaf - Senior Vice President and Chief Financial Officer Laurie S. Alsup - Director Eran Broshy - Director Peer Information Theravance Biopharma, Inc. (GSAC) Theravance Biopharma, Inc. (CASIF) Theravance Biopharma, Inc. (ALCD.) Theravance Biopharma, Inc. (OMNN) Theravance Biopharma, Inc. (CGPI.) Theravance Biopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G8807B106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 51.92 Most Recent Split Date: (:1) Beta: 0.25 Market Capitalization: $883.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.56 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: 10.90 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.03 Price/Cash Flow: - Price / Sales: 8.47 EPS Growth vs. Year Ago Period: -93.52% vs. Previous Quarter: 216.67% Sales Growth vs. Year Ago Period: -20.86% vs. Previous Quarter: 17.13% ROE 06/30/26 - -0.77 03/31/26 - 18.84 12/31/25 - 16.76 ROA 06/30/26 - -0.46 03/31/26 - 10.94 12/31/25 - 9.23 Current Ratio 06/30/26 - 13.54 03/31/26 - 13.14 12/31/25 - 10.93 Quick Ratio 06/30/26 - 13.54 03/31/26 - 13.14 12/31/25 - 10.93 Operating Margin 06/30/26 - -2.05 03/31/26 - 44.83 12/31/25 - 35.88 Net Margin 06/30/26 - 51.58 03/31/26 - 104.34 12/31/25 - 98.54 Pre-Tax Margin 06/30/26 - 56.48 03/31/26 - 124.72 12/31/25 - 120.27 Book Value 06/30/26 - 5.62 03/31/26 - 5.64 12/31/25 - 5.86 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©